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A
Absolute blood volume, optical measurement, HD 255
Acid-base balance
bicarbonate exit, proximal tubular cells 1671
D-lactic acidosis, GI tract 1
intracellular pH, sodium bicarbonate therapy 1262
ion exchangers mediating NaC1 transport 1665
metabolic alkalosis, Nephrology Forum 906
urine acidification, apical membrane-associated
particles 1655
urine acidification, distal 1660
urine pH and trimethoprim antikaliuresis 82
Acidosis
D-lactic, gastrointestinal tract 1
distal tubular, urolithiasis, Sjogren's syndrome (abst) 920
glucocorticoids and catabolism 679
intracellular pH, sodium bicarbonate therapy 1262
metabolic, CAPD and whole body protein degradation . 1396
NO-induced hypoxic tubular injury 1314
Acquired immunodeficiency syndrome (AIDS)
molecular analysis, human glomerular disease 53:S-21
TGF-j31 regulation with TGF-131 antisense oligomer. . . 53:S-2
trimethoprim and hyperkalemia 82
Actin, hypertensive glomerular damage, non-muscle
myosirl 55:S-169
Acute renal failure (ARF)
adsorption by HD membranes 309
contrast-media induced 1268
myoglobinuric, cytochrome P-450, catalytic iron 362
myohemoglobinuria and rhabdomyolysis 314
Acute tubular necrosis (ATN)
intrarenal IGF-I response to GH and EGF 344
phenotypic analysis, renal EC (abst) 931
Adenosine
receptors, chloride secretion, shark rectal gland 1557
renal responses to contrast medium 1199
Adhesion molecule interactions in human GN 127
Adrenomedullin, proadrenomedullin N-terminal 20
peptide, RF 55:S-148
Adult polycystic kidney disease (APKD)
Ang 11, indomethacin, renal function (abst) 922
post-transplant (abst) 931
Advanced glycation end products (AGEs)
modification of 132-m by 3-DG 861
monocyte/macrophage response to f32-m 538
Advanced oxidation protein products in uremia 1304
Afferent arterioles
flow modulates Ang II, glomerular hemodynamics 374
renal NO in essential hypertension 55:S-129
renin release and NO 626
vasopressin V2 receptors 722
Age
BP and progression of RF in elderly 55:S-75
protein glycation in kidney, DM, Nephrology Forum . . . 1795
renal response to L-Arg infusion, EH 55:S-126
Albumin, peritoneal permeability in diabetic rats 705
Albuminuria
antihypertensive therapy, NIDDM 55:S-91
microalbuminuria, antihypertensive therapy, NIDDM. 55:S-85
microalbuminuria, insulin resistance, hypertension
(abst) 925
microalbuminuria, LV mass, ABPM in EM 55:S-81
regional differences, American Indians 557
Alcoholism, rhabdomyolysis, myohemoglobinuric ARF .... 316
Aldosterone, potassium homeostasis 1738
Alkalosis, metabolic, cellular basis, Nephrology Forum . . . . 906
Allografts. See also Rejection
hypertensive recipients, calcium antagonists and ACEi. 55:S-97
intragraft TGF-/31 mRNA, interstitial fibrosis,
nephropathy 1297
loss, risk factors with SLE 512
monitoring AZA therapy (abst) 931
OKT3 prophylaxis, prolonged cold ischemia 768
a1-antitrypsin deficiency, PR3-ANCA vasculitis (abst) 919
Alport syndrome, spectrum of mutations 814
Aluminum hydroxide as phosphate binder, compared,
calcium carbonate (abst) 926
Ambulatory blood pressure monitoring (ABPM)
cardiovascular risk, hypertension 55: S-63
microalbuminuria, LV mass, EH 55:S-81
American Indians, albuminuria, regional differences 557
Amiloride-sensitive Na channels, molecular biology 1632
Amino acids
cystinuria, type I mutations, Quebec 1401
gated chloride channels, cytoprotection of EC 449
ingestion and peritoneal dialysate 1270
Amlodipin, blood flow after therapy (abst) 924
Amyloidosis
AGE modifies 132-m by 3-DG 861
AGEs, monocyte/macrophage response to f32-m 538
MD-related, systemic monocyte activation 506
Angiography
MRA flow measurements in HD grafts 903
non-ionic contrast media, severe CRF (abst) 929
Angioplasty
PTRA improves renal function in treated kidney (abst).. 923
Angiotensin-converting enzyme (ACE)
ACE and chymase in cardiovascular tissues 55:S-18
ACE-D allele and renal artery stenosis 534
gene insertion/deletion polymorphism 55:S-101
RAS polymorphisms in IgA nephropathy 571
Angiotensin-converting enzyme (ACE) inhibition
antiproteinuric effect, BP reduction 174
matrix gene expression, renal fibrosis 54:S-83
quinapril, adrenergic parameters, EH 55:S-104
renal hemodynamics, CsA and calcium antagonists . . 55:S-97
therapeutic advantages in CRF 55:S-57
Angiotcnsin II (Ang U)
antagonists, renal effects 1787
flow modulates, in microperfused afferent arterioles 374
glomerulosclerosis, stroke-prone SHR 55:S-109
indomethacin, renal effects with ADPKD (abst) 349
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renal arteriolar responsiveness and TGF 34
type 2 receptor, differential inducibility, hypertension. 55:S-14
Anions
organic, renal secretion 1649
single channel properties of VSOAC 1695
Anti-glomerular basement membrane nephritis
acute passive, P-selectin-deficient mice 1342
epitope specificity with synthetic peptides (abst) 927
rapid screening test (abst) 927
Anti-neutrophil cytoplasmic autoantibodies (ANCA)
a1-antitrypsin deficiency, PR3-ANCA vasculitis (abst) . . . 919
rapid screening test (abst) 927
Anti-Thy-i antibodies induce rat MC apoptosis 403
Antibodies
anti-Fas, cytolysis, apoptosis in human MC 1064
anti-GBM, ANCA, rapid screening test (abst) 927
anti-GBM, epitope specificity with synthetic peptides
(abst) 927
anti-SS-A, urolithiasis, distal tubular acidosis (abst) 920
anti-Thy-i, apoptosis in rat MC 403
autoreactive T-cells, Goodpasture's syndrome 1127
induce GN, anti-inflammatory lymphokines 117
lupus autoantibodies, cell surface antigens 1214
SjOgren's syndrome, hypocitraturic stones (abst) 920
Anticoagulation, citrate compared to LMWH in HD 806
Antidiuretic hormone (ADH), cellular/molecular action . . 1700
Antigens
cell surface and lupus autoantibodies 1214
TIN, receptors in proximal tubular EC 153
Antihypertensive therapy
ABPM for hypertension, cardiovascular risk 55:S-63
benazepril, renal effects in humans 55:S-i07
blood pressure as ESRD risk factor 55:S-69
BP, progression of RF in elderly 55:S-75
diltiazem, renal effects 55:S-78
effects on NOS, rat kidneys 55:S-138
felodipine and nephrotoxicity 55:S-94
flow properties of blood after (abst) 924
hemodynamics, CsA and ACEi 55:S-97
hypertension, progression of RF 55:S-72
hypertension, renal function, NIDDM 55:S-88
microalbuminuria, LV mass, ABPM, EH 55:S-81
nitrendipine, enalapril in NIDDM 55:S-85, 55:S-91
prognosis in diabetic nephropathy 1778
renal protection and ACE inhibitors 55:S-57
renal protection and Ca channel blockers 55:S-52
Apical localization of Na-K-Cl cotransporter, rats 40
Apical membrane-associated particles, urine acidification . 1655
Apoptosis
anti-Fas antibodies, cytolysis in human MC 1064
antibody induced, rat MC 403
compared, necrotic cell death 355
cystic and dysplastic renal development 135
glomerulosclerosis and 103




AQP-2, postobstructive polyuria (abst) 922
renal 1712
Arachidonic acid
hypoxic injury, rat proximal tubules 620
metabolism, macrophage dysregulation, CAPD 525
Arginine
metabolism along PT, biochemical heterogeneity 1608
Vi and V2 action of AVP, in rabbit CCD 55:S-177
Atherosclerosis
renovasculopathies of nephrosclerosis 564
scavenger receptors, monocyte-macrophages, HD 773
Atherothrombosis, high-dose B-vitamins, homocysteine,
ESRD, HD 147
Atrial natriuretic factor (ANF)
pressure dependent renin release, dogs (abst) 922
volume control, role in 1732
Autoimmune nephritis, serum CSF-1, mice 67
Autosomal dominant polycystic kidney disease
(ADPKD), fluid secretion by polycystic epithelia 1586
Azathioprine, measuring metabolites, allograft recipients
(abst) 931
B
B-vitamins, high-dose, lower homocysteine in dialysis 147
Banif Scores, clinical relevance 481
Basement membrane
in development, renal fibrosis and 54:S-68
thin GBM disease, loin pain-hematuria syndrome 168
tubular, pexicrine effects, paracrine signaling 48
Benazepril, renal effects in humans 55:S-107
f32-microglobulin (132-m)
AGE modification by 3-DG 861
AGEs, monocyte/macrophage response, amyloidosis .... 538
HD membranes, adsorption by 311
Betaine cotransporter, regulation by tonicity 1682
Bicarbonate exit from proximal tubular cells 1671
Bilateral (BUO) postobstructive polyuria, AQP-2 water
channel (abst) 922
Biocompatibility
bicarbonate buffered PD fluids, cell function 1447
nutritional parameters, chronic HD 551
systemic inflammatory effects of CAPD 506
Bioimpedance spectroscopy assesses fluid distribution . . . . 1105
Biopsy, renal
acute rejection, Banff Scores correlation 481
molecular analysis, human glomerular disease 53:S-21
T-cell genes and rejection 53:S-7
Blood coagulation proteins and stone matrix 880
Blood flow properties and antihypertensive therapy
(abst) 924
Blood pressure. See also Hypertension
ABPM, microalbuminuria, LV mass, EH 55:S-81
ABPM for hypertension, cardiovascular risk 55:S-63
circadian profiles, pediatric transplantation 55:S-175
control, dry body weight, chronic HD (abst) 925
insulin resistance in DN, familial clustering (abst) 924
insulin sensitivity, blood viscosity, women (abst) 925
intradialytic, dialysate Na profile (abst) 930
pregnancy, hypertension, 7-year follow-up (abst) 923
progression of RF in elderly 55:S-75
protein intake, renal disease progression 1783
reduction, antiproteinuric effect of ACEi 174
risk of ESRD 55:S-69
salt sensitivity, urinary kallikrein 11422
Blood volume
absolute, optical measurement, HD 255
children with NS 1471
vena cava inferior diameter, intra- and post-HD (abst) . . 930
Bone disease
children, calcitriol therapy, secondary
hyperparathyroidism 53:S-135
growth hormone, children 53:S-126
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hypercalciuria and cytokines 244
idiopathic hypercalciuria, Nephrology Forum 1507
nasal calcitonin, post-transplant bone loss (abst) 926
Bone metabolism and Pi transport 968, 975
Brain
cognitive function, chronic HD, ESRD 1435
cognitive function post-transplant 833
glutathione depletion in hyponatremia 470
Brequinar sodium, mechanisms of action 53:S-32
Brush-border membranes, Na/Pa cotransport regulation,
proximal tubules 1769
C
c-fos expression, heparin inhibits in MC 437
C-type natriuretic peptide, action in humans, CRF ... 55:S-144
C5b-9, mesangioproliferative GN 335
134Cs-trapping in frog skin epithelium 1568
Calcitonin, reduces post-transplant bone loss (abst) 926
Calcitriol
Ca metabolism disturbances, uremia 1765
children, bone disease, secondary
hyperparathyroidism 53:S-135
metabolism, zinc, peritoneal dialysis 1407
production, P11-I and dietary phosphorus 1441
Calcium
absorption, phosphorus intake, polyamine intestinal
function 499
dietary, urinary oxalate excretion in health 200
handling, renal abnormality in SHR 55:S-166
sympathetic adrenal tone, EH, women (abst) 930
Calcium (Ca2)
CCB inhibitory effect, human MC 868
cytosolic elevation, P depletion, rat cardiac myocytes. . . . 251
extracellular Ca2-sensing receptor 1042
intracellular, H202 increases in rat MC 388
membrane damage and Ca2-paradox 639
metabolism disturbances, calcitriol, RF 1765
set point, how plasma calcium is held constant 1760
set point, PTH reduction, HD 226
Calcium carbonate as phosphate binder, compared,
aluminum hydroxide (abst) 926
Calcium channel blockers
glomerular hemodynamics, effects on 55:S-132
improve renal function in CsA therapy (abst) 921
inhibit human mesangial cells 868
renal hemodynamics, CsA and ACEi 55:S-97
renal hemodynamics, gradated UUO, pigs (abst) 929
renal protection 55:S-52
Calculi
oxalate excretion in health 200
oxalate induces oxidant stress in tubules 413
CAPD. See Continuous ambulatory peritoneal dialysis
(CAPD)
Carboxyl terminal sequence, rat kidney laminin yl chain
synthesis 752
Cardiac myocytes, cytosolic Ca elevation, phosphate
depletion, rats 251
Cardiovascular system
ABPM for hypertension 55:S-63
ACE and chymase in heart and vessels 55:S-18
cardiomyopathy, ESRD morbidity/mortality 1379
heart transplant, 5-year study (abst) 931
heart transplant, pediatric 53:S-85
ischemic heart disease and chronic uremia 1428
organ damage in hypertension (abst) 923
renal disease, complications of (abst) 919
Carnitine metabolism in RF, CAPD 158
Catabolism
cholesterol, in nephrosis 855
glucocorticoids and acidosis 679
Cations, organic, renal secretion 1649
Cefuroxime reduces peritonitis, CAPD (abst) 926
Cell death
hypoxic injury, DNA damage, endonuclease activation... 355
programmed. See Apoptosis
Cell membranes, fatty acids and oxidant injury 88
Cell volume regulation, organic osmolytes
channels, transport characteristics/regulation 1690
coordination in renal cells 1684
myo-inositol, betaine cotransporters by tonicity 1682
osmoregulation in renal papilla 1686
single channel properties, volume sensitive anion
channel 1695
transcriptional responses, tubule challenges 1678
Chemical hypoxic injury, LLC-PK1 cells, endonuclease
activation 355
Children. See also Pediatric nephrology
circadian BP profiles, transplantation 55:S-175
growth retarded, CR1, rhGH therapy 781
NS, blood volume, colloid osmotic pressure, F-cell
ratio 1471
China, ESRD in, Nephrology Forum 287
Chloride channels, cytoprotection of EC 449
Chloride secretion, adenosine receptors, shark rectal
gland 1557
Chloride transport
chloride cells and osmoregulation 1563
electroneutral Na-(K)-Cl cotransporters 1638
shark rectal gland 1552
Cholesterol catabolism in nephrosis 855
Chronic renal failure (CRF)
adsorption by HD membranes 310
advanced, IGF-1 pharmacokinetics 1134
angiography with non-ionic contrast media (abst) 929
children, GH and bone disease 53:S-126
children, GH-IGF1 axis 53:S-109
children, GH release testing 53:S-123
hypertensive dialysis patients, mortality in 55:S-173
pathogenesis 54:S-2
peritoneal dialysate, Na pump inhibitor isolated 420
renal protection by ACEi 55:S-57
Chronic renal insufficiency (CR!)
children, rhGH, clinical update 53:S-115
children, rhGH, prior testing for GH release 53:S-1 19
children, rhGH therapy 781
Chymase in cardiovascular tissues, ACE 55:S-18
Circadian rhythms
macromolecular transport 1242
nocturnal BP elevation, pediatric transplantation . . . 55:S-175
Citrate compared to LMWH, hemodialysis 806
Clinical medicine and nephrology 1534
Cognitive brain function
chronic HD patients, ESRD 1435
post-transplant 833
COL4A5, spectrum of mutations, Alport syndrome 814
Collagen type IV, autoreactive T-cells, Goodpasture's. . . . 1127
Collecting ducts, inner medullary, active urea transport,
rats 1611
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Colony-stimulating factor-i (CSF-i), murine
autoimmune nephritis 67
Commerce in transplantation, Third World countries 1181
Complement
adsorption by HD membranes
C5b-9, mesangioproliferative GN
components in human kidneys
factor D adsorption by HD membranes
Computed tomography (CT), intrarenal BE,
hypertension
Congenital nephrotic syndrome, Finnish type
Congenital oligonephropathy, essential hypertension
Continuous ambulatory peritoneal dialysis (CAPD)
apoptosis of monocytes
carnitine metabolism, RF
cefuroxime reduces peritonitis (abst)
ingestion and peritoneal dialysate 1270
macrophage dysregulation 525
metabolic acidosis, whole body protein degradation. . . . 1396
peritoneal T-cell selection impaired 1386
systemic inflammatory effects 506
zinc modulates calcitriol metabolism 792
Contrast media
adenosine role in renal responses 1199
non-ionic, angiography, severe CRF (abst) 929
renal medullary blood flow 1268
Cortical collecting ducts (CCD), Vi and V2 action of
AVP, rabbits 55:S-i77
Cortical interstitial cells and tubular injury 54:S-28
"Crush syndrome," 314, 315
Cryoglobulins induce "wire-loop" lesions, PMN 647
Cyclic adenosine monophosphate (cAMP), regulates
trafficking, epitope-tagged CFTR 1642
Cyclosporine (CsA)
felodipine improves renal function (abst) 921
renal hemodynamics, antihypertensive therapy 55:S-97
with sirolimus, stable transplant patients 209
Cyclosporine (CsA) nephrotoxicity
felodipine improves renal function 55:S-94
phenotypic analysis, renal EC (abst) 931
rat model of renal transplant 1283
TGF-pl role 1141
Cystic fibrosis transmembrane conductance regulator
(CFTR), trafficking of epitope-tagged 1642
Cystinuria, molecular genetics, type I mutations, Quebec. . 1401
Cytochrome P-450 in myoglobinuric ARF 362
Cytokines
adsorption by HD membranes 310
bone disease, idiopathic hypercalciuria 244
synthesis, macrophage dysregulation, CAPD 525
Cytomegalovirus (CMV), molecular analysis, human
glomerular disease 53:S-21
Cytoprotection, EC, amino acid gated chloride channels. . . 449
Cytoskeleton and matrix assembly 54:S-64
Cytotoxicity, EC, H202-induced, lipid peroxidation 88
D
D-lactic acidosis 1
Deoxyspergualin (gusperimus), mechanisms of action . . 53:S-34
Diabetes insipidus
familial neurogenic, new VP-NPII mutations (abst) 924
vasopressin receptors 1706
Diabetes mellitus
IDDM, renal diagnoses other than DN (abst) 924
NIDDM, antihypertensive therapy 55:S-85, 55:S-91
NIDDM, renal function, hypertension 55:S-88
peritoneal permeability, albumin, rats 705
protein glycation in kidney, aging, Nephrology Forum . . 1795
Diabetic nephropathy (DN)
glomerular TGF-j31 1120
heparan sulfate metabolism 1079
prognosis, long-term antihypertensive therapy 1778
raised BP, insulin resistance, familial clustering (abst) . . . 924
renal diagnoses other than (abst) 924
tubulointerstitial changes 54:S-10
Dialysate
bicarbonate buffered, PD, cell function 1447
glucose, amino acids, malnutrition, CAPD 1270
peritoneal, Na pump inhibitor isolated 420
sodium profile, intradialytic BP (abst) 930
ultrapure vs. non-sterile, inflammatory response, in
vitro HD 236
Dialysis. See also Continuous ambulatory peritoneal
dialysis (CAPD); Hemodialysis
apoptosis of monocytes 792
body composition measured by DXA, EPO therapy
(abst) 928
high-dose B-vitamins lower homocysteine 147
hypertension as mortality risk factor 55:S-173
peritoneal, NAPRTCS database 53:S-68
scavenger receptors, monocyte-macrophages 773
Diet
Ca intake, urinary oxalate excretion in health 200
Na/P1 cotransport regulation, proximal tubules 1769
nutritional status, ingestion and peritoneal dialysate. . . . 1270
nutritional status, membrane biocompatibility, chronic
HD 551
phosphorus intake, polyamine intestinal function,
uremia 499
phosphorus intake, PTH, calcitriol production 1441
Pi intake, Na/P1 cotransport adaptation 1012
Diltiazem, renal effects of prolonged therapy 55:S-78
Diuresis pressure, NO, PG inhibition, hypertension. . . 55:S-14i
DNA
endonuclease-induced damage, chemical hypoxic
injury, LLC-PK1 cells 355
molecular analysis, human glomerular disease 53:S-21
Donnan system, fluid secretion, aglomerular/glomerular
kidneys 1543
Donor kidneys
cadaveric, 10-year outcome, pediatric 53:S-72
unrelated living donors (abst) 926
Dry body weight, volume status, BP control, chronic HD
(abst) 925
Dual-energy x-ray absorptiometry (DXA), body
composition, EPO, dialysis (abst) 928




ANF and volume control
calcitriol in renal failure
endogenous ouabain, hypertension
how plasma calcium is held constant
juxtaglomerular apparatus
NO, renal hemodynamics
proximal tubule Na/P1 cotransport
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Electroneutral Na-(K)-Cl cotransporters 1638
1 1f3-hydroxysteroid dehydrogenase (HSD),
immunolocalization of NAD-dependent 271
11 /3-hydroxysteroid-oxido-reductase, different mammalian
organs 55:S-156
Enalapril
diabetic hypertension with microalbuminuria 55:S-85
halts tubulointerstitial fibrosis 54:S-83, 1110
with hydrochlorothiazide in hypertension (abst) 923
improves albuminuria, GFR in NIDDM 55:S-91
End-stage renal disease (ESRD)
blood pressure as risk factor 55:S-69
in China, Nephrology Forum 287
hypertension, cardiomyopathy and morbidity/mortality.. 1379
neurocognitive function, chronic HD 1435
predictors, mass screening 800
Endonuclease activation in hypoxia 355
Endoplamsic reticulum phosphate transport 953
Endothelin-1 (ET-1) production, human MC and ROS.... 181
Endothelin (ET)
mitogenic action, GN in rats 1320
peptides localized in human kidney 382
renin regulation, role in 55:S-119
TGF, role in with NO 55:S-135
Epidermal growth factor (EGF)
expression and its receptor 656
response of intrarenal IGF-I, ATN 344
Epithelial cells
134Cs-trapping, frog skin epithelium 1568
cell surface polarity and membrane dysfunction 1592
cytoprotection and chloride channels 449
fluid secretion by polycystic epithelia 1586
HSPG production and high glucose 1079
lipid peroxidation, H202 cytotoxicity 88
Na/P1, ion transporter interactions 988
phenotypes, post-transplant with complications (abst) . . . 931
Pi transport in ruminants 992
PT, TIN-ag receptors in 153
renal Na/P1-cotransporters 981
tubular BM, pexicrine effects, paracrine signaling 48
type I and II Na/P transporters 986
Erythropoietin (EPO), DXA, body composition, dialysis
(abst) 928
Escherichia coli genes, Pi regulation of 964
Essential hypertension
aging and renal response to L-Arg infusion 55:S-126
Ca, sympathetic adrenal tone, women (abst) 930
congenital oligonephropathy 55:S-30
CT-derived RBF 846
defective renal NO synthesis 55:S-129
microalbuminuria, LV mass, ambulatory BP 55:S-81
pressure-volume regulation 55 :S-35
primary hypertension, transplantation 55:S-42
quinapril, adrenergic inhibition with 55:S-104
renal hemodynamics, CT-derived RBF 846
salt and hypertension 55:S-46
Evolutionary aspects, renal function 1539
Extracellular fluid volume (ECV), dry BW
determination, BP control, HD (abst) 925
Extracellular matrix (ECM)
cell-matrix interactions, glomerular mesangium 1575
glomerulosclerosis 605
MMPs in renal fibrosis 54:S-61
remodeling, basement membrane in development . .. 54:S-68
renal tubulo interstitial interaction 48
synthesis and morphine 94
Extracellular nucleotides modulate Pi transport 1019
F
F-cell ratio, blood volume in children with NS 1471
Factor H deficiency, MPGN type II, pigs (abst) 918, 928
Familial neurogenic diabetes insipidus, new VP-NPII
mutations (abst) 924
Fanconi syndrome, glycine attenuates renal injury in vivo .. 684
Fas, human MC cytolysis and apoptosis 1064
Felodipine, improves renal function, CsA 55:S-94, 921
Fibronectin deposits, glomerulopathy with (abst) 919
Fibrosis. See also Renal interstitial fibrosis
hepatic fibrogenesis 54:S-39
pulmonary, myofibroblast role 54:S-46
FK506
mechanisms of action 53:S-26
renal and hormonal effects, pigs (abst) 921
Fluid secretion
common mechanism, aglomerular/glomerular kidneys . . 1543
by polycystic epithelia 1586
Fluvastatin lowers atherogenic lipids, post-transplant
(abst) 927
Focal segmental glomerular sclerosis (FSGS), children . 53:S-57
Free radicals
lipid peroxidation during myohemoglobinuria 741
oxalate toxicity in LLC-PK1 cells 413
Furan dicarboxylic acid, plasma clearance, uremic rats 634
G
G-protein-coupled receptor kinases 1047
Gastrointestinal tract
D-lactic acidosis I
intestinal function, polyamine metabolism 499
Gene therapy, progress in human 1791
Genetics
ACE-D allele and renal artery stenosis 534
ACE gene polymorphism 55:S-101
chromosomal localization, rat kidney PG EP3
receptor 55:S-183
COL4A5 mutations, Alport syndrome 814
cystinuria, type I mutations, Quebec 1401
familial clustering, raised BP, insulin resistance in DN
(abst) 924
glomerulopathy with predominant fibronectin deposits
(abst) 919
hepatic cholesterol 7a-hydroxylase, nephrosis 855
HLA-DQ gene polymorphism in IgAN 477
promotion of interstitial fibrosis, rats 54:S-49
RAS polymorphisms in IgAN 571
renal gene transfer 612
susceptibility to nephropathia epidemica, Puutnala
hantavirus 217
vascular PTHrP gene expression regulation 55:S-154
VP-NPII mutations, familial neurogenic DI (abst) 924
VP-NPII precursor, mutations, mammalian cell lines
(abst) 928
X-linked hypophosphatemia 1027, 1033
Glomerular disease
molecular analysis, human 53:S-21
myosin heavy chain, nonmuscle 1231
TGF-/3 isoforms, humans 461
thin GBM disease, loin pain-hematuria syndrome 168
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Glomerular filtration rate (GFR)
antihypertensive therapy, NIDDM 55:S-91
mesangiolysis interferes with autoregulation (abst) 922
Glomerular function
circadian rhythm in macromolecular transport 1242
fluid secretion, dynamic Donnan system 1543
mesangium, roles of 1583
post-heart transplant, 5-year study (abst) 931
Glomerular hemodynamics
arteriolar Ang II responsiveness and TGF 34
Ca antagonists, effects on 55:S-132
flow modulates Ang II in afferent arterioles 374
macula densa derived NO regulates GC 430
Glomerular injury with sickle cell anemia 786
Glomerular mesangial cells
antibody induced apoptosis, rats 403
cell-matrix interactions 1575
T-SV4O immortalized cells, human 267
tyrosine phosphorylation of JAK 1 protein by PDGF 19
Glomerulonephritis (GN)
adhesion molecule interactions, humans 127
anti-inflammatory lymphokines 117
brain/embryo-type myosin heavy chain 1350
experimental autoimmune, Goodpasture's epitope, rats. . 327
factor H deficiency causes MPGN, pigs (abst) 928
L-Arg depletion, nephrotoxic nephritis 1090
MIP-2 and MCP-1 expression 715
mitogenic action of ET, rats 1320
MPGN, factor H deficiency, pigs (abst) 918
Glomerulopathy
pathogenesis of CRF 54:S-2
with predominant fibronectin deposits (abst) 919
Glomerulosclerosis (GS)
apoptosis in 103
CsA-induced, rat model 1283
extracellular matrix 605
focal segmental, children 53:S-57
focal segmental, familial/sporadic forms (abst) 920
increased urinary TGF-pl (abst) 920
lipoproteins and fibrosis 54:S-18
RAS, hemodynamics, TGF-13, SHRSP 55:S-109
TCV-116, tubulointerstitial fibrosis, rats 55:S-115
Glomerulus
anatomy and pathology 1570, 1575, 1583, 1586, 1592
hypertensive damage, actin and myosin 55:S-169
lupus autoantibodies, cell surface antigens 1214
stability/leakiness, opposing challenges of 1570
Glucocorticoids, acidosis and catabolism 679
Glucose, high, HSPG production, mesangial and
epithelial cells 1079
Glucose ingestion and peritoneal dialysate 1270
Glutathione, brain, depletion in hyponatremia 470
Glycine
attenuates Fanconi syndrome 684
NO-induced hypoxic tubular injury 1314
Goodpasture's syndrome
autoreactive T-cells 1127
epitope, nephritogenicity, GN in rats 327
Growth, Pi reabsorption during 1023
Growth factors, renal disease and (abst) 918
Growth hormone (GH)
bone disease in children 53:S-126
GH-IGF1 axis with CRF 53:S-109
IGF-1 additive effects, uremia 1413
release, testing for 53:S-119, 53:S-123
response of intrarenal IGF-I, ATN 344
treatment, children, post-transplant 53:S-128
Growth patterns
children, CR1, rhGH therapy 781
children with CR1, rhGH, clinical update 53:S-115
post-transplant in children 53:S-103
Gusperimus (deoxyspergualin), mechanisms of action .. 53:S-34
Guy's Hospital, Mahomed's description of hypertension . . 1488
H
Hantavirus, Puumula and nephropathia epidemica 217
Heart transplantation
glomerular/tubular functions, 5-year study (abst) 931
pediatric population 53:S-85
Hematuria
hypertensive pregnancy, 7-year follow-up (abst) 923
idiopathic non-proteinuric 222
loin pain (LPH syndrome), thin GBM disease 168
Hemodialysis. See also Dialysate
adsorption by membranes 309
apoptosis of monocytes 792
CaCO3 vs. Al(OH)2 as phosphate binder (abst) 926
chronic, neurocognitive function 1435
citrate compared to LMWH 806
dry body weight, volume status, BP control (abst) 925
fluid distribution assessed with bioimpedance 1105
HCV, molecular evidence, nosocomial transmission 889
HCV, phylogenetic analysis of isolates 896
home vs. center, mortality compared 1464
implementing a quality improvement project (abst) 930
iohexol clearance, residual renal function 232
magnesium carbonate as P binder 163
MRA flow measurements in HD grafts 903
nutritional status and biocompatibility 551
optical measurement of absolute BV 255
pediatric, past to future 53:S-64
set point of Ca and PTH reduction 226
survival/mortality, risk factors (abst) 929
vascular access, 15-year study (abst) 925
vascular access recirculation monitor 1152
vascular access stenosis, Nephrology Forum 1161
vena cava inferior diameter, blood volume, intra- and
post-HD (abst) 930
Hemolytic uremic syndrome (HUS), bilateral
nephrectomy to cure 282
Hemorheological factors, insulin sensitivity, BP, women
(abst) 925
Hemorrhagic fever with renal syndrome (HFRS),
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